Year: 2012
Type: article
Abstract: There is strong evidence that both adoptive T cell transfer and T cell checkpoint blockade can lead to regression of human melanoma. However, little data are available on the effect of these cancer therapies on the tumor-reactive T cell compartment. To address this issue we have profiled therapy-induced T cell reactivity against a panel of 145 melanoma-associated CD8(+) T cell epitopes. Using this approach, we demonstrate that individual tumor-infiltrating lymphocyte cell products from melanoma patients contain unique patterns of reactivity against shared melanoma-associated antigens, and that the combined magnitude of these responses is surprisingly low. Importantly, TIL therapy increases the breadth of the tumor-reactive T cell compartment in vivo, and T cell reactivity observed post-therapy can almost in full be explained by the reactivity observed within the matched cell product. These results establish the value of high-throughput monitoring for the analysis of immuno-active therapeutics and suggest that the clinical efficacy of TIL therapy can be enhanced by the preparation of more defined tumor-reactive T cell products.
Source: OncoImmunology
DOI: 10.4161/onci.18851
Authors: Pia Kvistborg, Chengyi Jenny Shu, Bianca Heemskerk, Manuel Fankhauser, Charlotte Albæk Thrue, Mireille Toebes, Nienke van Rooij, Carsten Linnemann, Marit M. van Buuren, Jos H.M. Urbanus, Joost B. Beltman, Per thor Straten, Yong F. Li, Paul F. Robbins, Michal J. Besser, Jacob Schachter, Gemma G. Kenter, Mark E. Dudley, Steven A. Rosenberg, John B.A.G. Haanen, Sine Reker Hadrup, Ton N.M. Schumacher
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,913
OpenAlex ID: W2154042746